Discover 290 paid clinical trials in Cape Coral, Florida. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 290
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
for
Ovarian Neoplasms, Fallopian Tube Neoplasms,
Location: Fort Myers FL, Fort Lauderdale FL, West Palm Beach FL,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT07213804
Phase3, Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
for
Breast Neoplasms
Location: Fort Myers FL, St. Petersburg FL, Palm Bay FL,
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT07173751
Phase3, Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
for
Prostate Cancer
Location: Fort Myers FL, Miami FL, Orlando FL, Charleston SC,
Sponsor: Novartis Pharmaceuticals
Sex: Male
Age: 18 - 70+
Code: NCT06855277
Phase3, Recruiting
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
for
Ovarian Cancer
Location: Fort Myers FL, West Palm Beach FL, Miami FL,
Sponsor: Incyte Corporation
Sex: Female
Age: 18 - 70+
Code: NCT07023627
Phase2, Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Location: Fort Myers FL, West Palm Beach FL, Saint Augustine FL,
Sponsor: Loxo Oncology, Inc.
Sex: All
Age: 18+
Code: NCT05254743
Phase3, Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
for
Leukemia, Myeloid, Acute
Location: Fort Myers FL, Weston FL, Tampa FL, Pembroke Pines FL,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06852222
Phase3, Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
for
Carcinoma, Non-Small-Cell Lung
Location: Fort Myers FL, St. Petersburg FL, Tampa FL,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06890598
Phase3, Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
for
Carcinoma, Non-Small Cell Lung,
Location: Fort Myers FL, Pembroke Pines FL, Hollywood FL,
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Sex: All
Age: 18+
Code: NCT04389632
Phase1, Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
for
Relapsed or Refractory Multiple Myeloma
Location: Fort Myers FL, St. Petersburg FL, Coral Springs FL,
Sponsor: Celgene
Sex: All
Age: 18+
Code: NCT05519085
Phase3, Recruiting
A Phase â…¢ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Location: Fort Myers FL, St. Petersburg FL, Plantation FL,
Sponsor: Shanghai Henlius Biotech
Sex: All
Age: 18+
Code: NCT06532006
Phase3, Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
for
Advanced HR+/HER2- Breast Cancer,
Location: Fort Myers FL, Nashville TN, Houston TX, St Louis MO,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT06726148
Phase1, Phase2, Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
for
Extensive-Stage Small Cell Lung Cancer
Location: Fort Myers FL, St. Petersburg FL, Orange City FL,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT06646276
Phase3, Recruiting
IC-8 Apthera IOL New Enrollment Post Approval Study
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)